Tumor heterogeneity: morphological, molecular and clinical

• Lleonart, M. E. ^[1] ; Martin-Duque, P. ^[1] ; Sanchez-Prieto, R. ^[1] ; Moreno, A. ^[1] ; Ramon y Cajal, S. ^[1]
  1. [1] Department a Pathology, Oinica Puerta de Hierro, Madrid, Spain
• Localización: Histology and histopathology: cellular and molecular biology, ISSN-e 1699-5848, ISSN 0213-3911, Vol. 15, Nº. 3, 2000, págs. 881-898
• Idioma: inglés
• Enlaces
  • Texto completo
• Resumen

  • Malignant tumors are characterized by their great heterogeneity and variability. There are hundreds of different types of malignant tumors that harbour many oncogenic alterations. The tumor heterogeneity has important morphological, molecular and clinical implications. Except for some hematopoietic and lymphoproliferative processes and small cell infant tumors, there are not specific molecular alterations for most human tumors. In this review we summarize the most important aspects of carcinogenesis and chemoradiosensitivity of malignant cells. In this regard, some oncogenes such as neu, ras and bcl-2 have been associated with cellular resistance to treatment with anticancer agents. The knowledge of oncogenic alterations involved in each tumor can be important to correlate the morphological features, the genetic background, the prognosis and the clinical response to treatment with anticancer agents. Based on the molecular background of the tumor there are new cancer gene therapy protocols. For example using adenovirus Ela in tumors with overexpression of neu oncogene, inhibitors of tirosine kinase specific for the PDGF receptor in glioma, inhibitors of farnesil transferase to prevent ras activity in tumors with mutations in the ras gene.